[1] Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61.
[2] Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159.
[3] The aging suppressor klotho: a potential regulator of growth hormone secretion, Shiri Shahmoon, Hadara Rubinfeld, Ido Wolf, Zvi R. Cohen, Moshe Hadani, Ilan Shimon, and Tami Rubinek, Journal of Physiology-Endocrinology and Metabolism Volume 307, Issue 3
[4] Peter B. Johansen, Jette Nowak, Christian Skjærbæk, Allan Flyvbjerg, Troels T. Andreassen, Michael Wilken, Hans Ørskov,
Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats, Growth Hormone & IGF Research, Volume 9, Issue 2, 1999, Pages 106-113
[5] Junichi Ishida, Masakazu Saitoh, Nicole Ebner, Jochen Springer, Stefan D. Anker, Stephan von Haehling, Growth hormone secretagogues: history, mechanism of action, and clinical development, JCSM Communications, Volume3, Issue1, January/June 2020, Pages 25-37
[6] Divall SA, Radovick S. Growth Hormone and Treatment Controversy; Long Term Safety of rGH. Curr Pediatr Rep. 2013 Jun 1;1(2):128-132.